NASDAQ$AMGN
Amgen Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Amgen's financial results for Q2 2022 were announced, demonstrating revenue growth and increased EPS.
Amgen reported a 1% increase in total revenues to $6.6 billion for Q2 2022. GAAP EPS increased to $2.45, and non-GAAP EPS increased to $4.65. The company generated $1.7 billion in free cash flow.
- Total revenues increased 1% to $6.6 billion, driven by growth in global product sales.
- GAAP EPS increased to $2.45, and non-GAAP EPS increased to $4.65, driven by lower operating expenses.
- Free cash flow remained consistent at $1.7 billion compared to Q2 2021.
- 2022 total revenues guidance revised to $25.5-$26.4 billion; EPS guidance revised to $11.01-$12.15 on a GAAP basis, and reaffirmed at $17.00-$18.00 on a non-GAAP basis.
Headline financials
Revenue & EPS history
Amgen · Revenue · Quarterly
$6.59B
Revenue by segment
Amgen · $5.67B total across 17 segments · Q2 2022
- Enbrel$1.05B-8.1%18.5%
- Prolia$922M+13.3%16.3%
- Otezla$594M+11.2%10.5%
- XGEVA$533M+9.2%9.4%
- Aranesp$357M-2.7%6.3%
- Repatha$325M+13.6%5.7%
- KYPROLIS$317M+13.2%5.6%
- Neulasta$310M-36.2%5.5%
- Nplate$284M+15.9%5.0%
- Vectibix$207M-13.4%3.7%
- EVENITY$191M+45.8%3.4%
- BLINCYTO$139M+28.7%2.5%
- AMJEVITA/AMGEVITA$116M+8.4%2.0%
- Other products$113M+46.8%2.0%
- Parsabiv$103M+45.1%1.8%
- LUMAKRAS/LUMYKRAS$77M—1.4%
- TEZSPIRE$29M—0.5%
Forward guidance
Amgen has revised its full year 2022 guidance, expecting total revenues to be in the range of $25.5 billion to $26.4 billion. GAAP EPS is projected to be between $11.01 and $12.15, while non-GAAP EPS is reaffirmed at $17.00 to $18.00.
Tailwinds
- Total revenues are expected to be in the range of $25.5 billion to $26.4 billion.
- Capital expenditures are projected to be approximately $950 million.
- Share repurchases are expected to be in the range of $6.0 billion to $7.0 billion.
- GAAP EPS in the range of $11.01 to $12.15.
- Non-GAAP EPS reaffirmed at $17.00 to $18.00.
Headwinds
- GAAP tax rate is expected to be in the range of 11.5% to 13.0%.
- Non-GAAP tax rate is expected to be in the range of 14.0% to 15.0%.
- Unspecified potential negative impacts from market competition.
- Unspecified potential negative impacts from pricing pressure.
- Unspecified potential negative impacts from reimbursement policies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+0.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+0.1%
Avg return
30 days after
53%
39 / 73 earnings
Positive
+12.2%
Q1 2024
Best reaction
-8.7%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | -4.4% | -2.7% | |
| Q4 2025 | +3.0% | +11.0% | +9.1% | |
| Q3 2025 | +7.7% | +9.1% | +11.2% | |
| Q2 2025 | -5.1% | -5.0% | -5.5% | |
| Q1 2025 | -1.1% | -2.8% | +1.6% | |
| Q4 2024 | +6.5% | +2.0% | +12.4% | |
| Q3 2024 | +1.3% | +0.3% | -10.5% | |
| Q2 2024 | -3.9% | -0.8% | -0.3% | |
| Q1 2024 | +12.2% | +8.3% | +10.3% | |
| Q4 2023 | -8.1% | -9.6% | -15.3% | |
| Q3 2023 | -0.9% | +2.5% | +2.5% | |
| Q2 2023 | +5.6% | +13.2% | +11.4% | |
| Q1 2023 | +0.4% | -1.2% | -9.2% | |
| Q4 2022 | -2.1% | -2.6% | -6.7% | |
| Q3 2022 | +0.0% | +8.7% | +6.1% | |
| Q2 2022 | -0.4% | +0.5% | -1.9% | |
| Q1 2022 | -4.7% | -7.6% | +2.2% | |
| Q4 2021 | +8.5% | +2.7% | +4.2% | |
| Q3 2021 | +4.0% | +1.9% | -4.1% | |
| Q2 2021 | -4.8% | -4.0% | -5.8% | |
| Q1 2021 | -7.4% | -6.2% | -7.9% | |
| Q4 2020 | -1.4% | -1.7% | -7.7% | |
| Q3 2020 | -2.5% | -1.5% | +0.6% | |
| Q2 2020 | -1.9% | -3.5% | -0.3% | |
| Q1 2020 | -2.0% | +0.3% | -2.5% | |
| Q4 2019 | -4.9% | -2.4% | -12.1% | |
| Q3 2019 | +2.9% | +6.3% | +14.4% | |
| Q2 2019 | +6.0% | +6.3% | +17.5% | |
| Q1 2019 | -2.8% | -2.1% | -6.7% | |
| Q4 2018 | -3.7% | -2.5% | -1.0% | |
| Q3 2018 | +2.4% | -0.6% | +7.5% | |
| Q2 2018 | -0.3% | +1.8% | +1.9% | |
| Q1 2018 | +0.1% | +1.6% | +1.9% | |
| Q4 2017 | +0.5% | -5.1% | -0.5% | |
| Q3 2017 | -2.1% | -3.2% | -5.7% | |
| Q2 2017 | -2.9% | -3.6% | -6.1% | |
| Q1 2017 | -1.2% | -1.3% | -5.9% | |
| Q4 2016 | +4.9% | +4.5% | +12.9% | |
| Q3 2016 | -8.7% | -11.5% | -8.5% | |
| Q2 2016 | +2.2% | +3.9% | +2.6% | |
| Q1 2016 | -1.7% | — | — | |
| Q4 2015 | +1.5% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q3 2014 | +6.7% | — | — | |
| Q2 2014 | +6.0% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +1.8% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -7.5% | — | — | |
| Q4 2012 | -0.8% | — | — | |
| Q3 2012 | +0.8% | — | — | |
| Q2 2012 | +7.6% | — | — | |
| Q1 2012 | +0.2% | — | — | |
| Q4 2011 | -0.8% | — | — | |
| Q3 2011 | +4.9% | — | — | |
| Q2 2011 | -3.0% | — | — | |
| Q1 2011 | -1.5% | — | — | |
| Q4 2007 | +0.7% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2008 | +0.7% | — | — | |
| Q3 2010 | -0.9% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2009 | +1.5% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | +0.5% | — | — | |
| Q3 2009 | +1.6% | — | — | |
| Q4 2008 | +3.8% | — | — | |
| Q2 2009 | +3.8% | — | — | |
| Q2 2008 | +3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro